Condition: Unresectable Melanoma · Metastatic Melanoma · Stage III Non-small Cell Lung Cancer · Sponsor: Iovance Biotherapeutics, Inc.
This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).
This description comes directly from the study's public registry record.
Iovance Biotherapeutics Study Team · 1-844-845-4682 · Clinical.Inquiries@iovance.com
Always discuss trial participation with your own doctor first.
| The Angeles Clinic and Research Institute | Los Angeles, California, United States | Recruiting |
| Sylvester Comprehensive Cancer Center | Miami, Florida, United States | Recruiting |
| Orlando Health Cancer Institute | Orlando, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| The University of Kansas Cancer Center | Westwood, Kansas, United States | Recruiting |
| University of Louisville | Louisville, Kentucky, United States | Recruiting |
| Weill Medical College of Cornell University | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| University of Cincinnati | Cincinnati, Ohio, United States | Recruiting |
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Recruiting |
| Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Withdrawn |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05361174